Introduction to CELMoDs in Relapsed/Refractory Multiple Myeloma

Cancer Network’s FACE-OFF introduces the evolving role of cereblon E3 ligase modulators, or CELMoDs, in relapsed/refractory multiple myeloma. Dr. Muhamed Baljevic welcomes viewers and outlines the program’s competitive format, with Team Catalyst and Team Compass presenting, debating, and responding to one another throughout the discussion. The program is organized into three sections: Data and Landscape, Hot Topics Debate, and Case-Based Discussion. The first section will examine emerging clinical evidence across the CELMoD landscape, including efficacy, safety, mechanism of action, and interpretation of clinical endpoints. The Hot Topics Debate will address key clinical and practical considerations related to treatment intensity, patient selection, sequencing, efficacy, safety, and treatment burden. Finally, the Case-Based Discussion will apply the evidence to patient scenarios, considering disease characteristics, prior treatment, patient factors, and treatment logistics in clinical decision-making. The faculty then introduce the members of both teams before beginning the evidence review.